Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

by Virginia L. Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari, Kathleen A. Day, Angelo Camporeale
Published 2020-05-01

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

by Virginia L. Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, Angelo Camporeale
Published 2020-06-01

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

by Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler, Virginia L. Stauffer
Published 2018-11-01